Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | FADS1 | O60427 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13734971 | 1.00 | MEN1 (0.75) | MEN1KMT2AKDM4ELMNAEGFR | |
| SCHEMBL25439873 | 1.00 | MEN1 (0.75) | MEN1KMT2AKDM4ELMNAEGFR | |
| SCHEMBL2096086 | 0.87 | FADS1 (0.59) | MEN1KMT2AKDM4ELMNAMTOR | |
| SCHEMBL28632640 | 0.84 | LMNA (0.54) | MEN1KMT2AKDM4ELMNAMTOR | |
| SCHEMBL13735092 | 0.84 | MEN1 (0.54) | MEN1KMT2AKDM4ELMNAMTOR | |
| SCHEMBL3719163 | 0.84 | MEN1 (0.54) | MEN1KMT2AKDM4ELMNAMTOR | |
| SCHEMBL24166526 | 0.84 | MEN1 (0.73) | MEN1KMT2AKDM4ELMNAEGFR | |
| SCHEMBL15652254 | 0.84 | MEN1 (0.53) | MEN1KMT2AKDM4ELMNAMTOR | |
| SCHEMBL24166613 | 0.83 | MEN1 (0.81) | MEN1KMT2AKDM4ELMNAEGFR | |
| SCHEMBL7356216 | 0.82 | MEN1 (0.53) | MEN1KMT2AKDM4ELMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | MEN1 4695/4885KMT2A 3485/4885KDM4E 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.